Ascendis Pharma A/S (ASND) Stock Price

223.82 ▼ -3.59 (-1.58%)
Open: 227.91 Vol: 553.69K Day's range: 219.835 - 228.03 Mar 19, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
ASND Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY SELL SELL SELL BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 222.62▲ 221.92▲ 221.87▲ 227.26▼ 229.79▼
MA10 222.52▲ 221.73▲ 223.62▲ 231.39▼ 225.47▼
MA20 221.90▲ 224.19▼ 226.15▼ 232.97▼ 216.54▲
MA50 221.45▲ 227.36▼ 228.20▼ 225.55▼ 195.36▲
MA100 223.43▲ 229.30▼ 233.32▼ 216.16▲ 165.47▲
MA200 226.04▼ 232.90▼ 229.02▼ 201.85▲ 136.49▲
  5 mins 30 mins Hourly Daily Weekly
MACD 0.153▲ 0.128▲ -0.361▼ -1.851▼ -0.141▼
RSI 68.429▲ 47.123▼ 43.472▼ 44.226▼ 55.349▲
STOCH 48.220     43.544     18.100▼ 19.826▼ 67.154    
WILL %R -1.645▲ -55.939     -65.788     -86.137▼ -40.926    
CCI 202.069▲ 33.104     -41.009     -123.345▼ 36.027    
Latest Filters Detected On ASND
MA $ASND Price Crossed Below MA(50) Set Alert
CDL $ASND Engulfing Candlestick Pattern Detected Set Alert
Ascendis Pharma A/S News
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Tuesday, March 17, 2026 06:48 AM
Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability ...
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
Monday, March 16, 2026 05:39 AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained ...
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia
Wednesday, March 04, 2026 08:01 PM
Ascendis Pharma A/S (NASDAQ:ASND) executives outlined plans for the U.S. launch of YUVIWEL following FDA approval, describing the product as the first once-weekly treatment for children with ...
ASND historical stock data
date open high low close volume
19/03/26 227.91 228.03 219.835 223.82 553,691
18/03/26 227.31 231.00 224.57 227.41 321,056
17/03/26 229.20 232.00 227.715 228.06 360,037
16/03/26 226.13 231.50 226.06 231.025 330,911
13/03/26 230.76 233.055 222.95 225.98 606,022
12/03/26 227.18 232.355 225.855 229.01 885,420
11/03/26 240.00 242.72 227.09 227.50 881,016
10/03/26 239.73 245.63 239.04 240.52 336,110
09/03/26 236.64 244.55 234.53 239.92 747,987
06/03/26 233.87 241.79 233.00 240.65 555,525
Quote Details
52wk Low:124.06
52wk High:248.58
Vol:553.69K
Avg Vol(3m):12.4M
1Y Chng:+56.88%
1M Chng:+2.96%
Add to Watch List
More Information
Index US Composite
Market Cap. 13.96B